Immunosuppression status of liver transplant recipients with hepatitis C affects biopsy-proven acute rejection
Clinical and Molecular Hepatology
;
: 366-371, 2016.
Article
in English
| WPRIM
| ID: wpr-188163
ABSTRACT
BACKGROUND/AIMS:
The relationship between patient survival and biopsy-proven acute rejection (BPAR) in liver transplant recipients with hepatitis C remains unclear. The aims of this study were to compare the characteristics of patients with and without BPAR and to identify risk factors for BPAR.METHODS:
We retrospectively reviewed the records of 169 HCV-RNA-positive patients who underwent LT at three centers.RESULTS:
BPAR occurred in 39 (23.1%) of the HCV-RNA-positive recipients after LT. The 1-, 3-, and 5-year survival rates were 92.1%, 90.3%, and 88.5%, respectively, in patients without BPAR, and 75.7%, 63.4%, and 58.9% in patients with BPAR (P<0.001). Multivariate analyses showed that BPAR was associated with the non-use of basiliximab and tacrolimus and the use of cyclosporin in LT recipients with HCV RNA-positive.CONCLUSION:
The results of the present study suggest that the immunosuppression status of HCV-RNA-positive LT recipients should be carefully determined in order to prevent BPAR and to improve patient survival.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Recurrence
/
Biopsy
/
Recombinant Fusion Proteins
/
RNA, Viral
/
Polymerase Chain Reaction
/
Survival Rate
/
Retrospective Studies
/
Liver Transplantation
/
Tacrolimus
/
Cyclosporine
Type of study:
Observational study
/
Prognostic study
/
Risk factors
Limits:
Humans
Language:
English
Journal:
Clinical and Molecular Hepatology
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS